ADMA BIOLOGICS, INC. 10-Q

Item 5. Other Information. None. Item 6. Exhibits See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q. 64 Index SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ADMA Biologics, Inc. Date: May 10, 2023 By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer Date: May 10, 2023 By: /s/ Brian Lenz Name: Brian Lenz Title: Executive Vice President and Chief Financial Officer 65 Index EXHIBIT INDEX Exhibit Number Description 4.1 Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the SEC on May 2, 2023). 10.1 Amendment No. 1 to Credit Agreement and Guaranty, dated March 22, 2023, by and among the Company, Hayfin Services LLP and the lenders party thereto (incorporated by reference to Exhibit 10.25.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2023). 10.2 Amendment No. 2 to the Credit and Guaranty Agreement, dated as of May 1, 2023, by and among the Company, Hayfin Services LLP and the lenders party thereto (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on May 2, 2023). 31.1* Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1** Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2** Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101* The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended March 31 2023, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2023 and 2022, (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) for the three months ended March 31, 2023 and 2022, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2023 and 2022, and (v) Notes to (Unaudited) Condensed Consolidated Financial Statements. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). * Filed herewith. ** In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed. 66